AbbVie Inc. is an American pharmaceutical company that focuses on the development and commercialization of advanced therapies to address various medical conditions. The company was founded on January 1, 2013, as a spin-off from Abbott Laboratories. It operates independently and has its headquarters in North Chicago, Illinois, USA.
AbbVie's primary areas of expertise include immunology, oncology, neuroscience, virology, and general medicine. The company is known for its flagship products, such as Humira (adalimumab), which is one of the world's best-selling drugs used to treat autoimmune diseases like rheumatoid arthritis, psoriasis, and Crohn's disease. Additionally, AbbVie's product portfolio includes treatments for chronic hepatitis C, Parkinson's disease, multiple sclerosis, and cancer.
As a global biopharmaceutical company, AbbVie operates in several regions, including North America, Europe, Asia-Pacific, and Latin America. It has a significant presence in the international healthcare market, collaborating with healthcare professionals and institutions to provide innovative solutions for patients worldwide.
Since its inception, AbbVie has been committed to research and development to introduce new and groundbreaking medicines. The company invests heavily in scientific innovation, clinical trials, and regulatory approvals to expand its product pipeline and improve patient outcomes. With a focus on cutting-edge research and strategic acquisitions, AbbVie strives to remain at the forefront of medical advancements and healthcare solutions.